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ABSTRACT
A 32-year-old woman undergoing an in vitro fertilization program was admitted to our hospital with the diagnosis of severe ovarian 
hyperstimulation syndrome (OHSS). Transvaginal ultrasonography showed two gestational sacs. Treatment with fluid restriction, serum 
albumin and intravenous furosemide was started, and repeated thoracentesis and paracenteses were performed. In the absence of clinical 
improvement, the patient was transferred to the intensive care unit and a therapeutic abortion was suggested. Due to the similarities between 
OHSS and idiopathic systemic capillary leak syndrome, we offered the patient compassionate treatment with intravenous immunoglobulins. 
After administration, the patient showed rapid improvement and we were able to suspend intravenous furosemide and serum albumin. She 
was discharged, and pregnancy has continued normally to date.
LEARNING POINTS
• OHSS is an infrequent yet serious complication of assisted reproductive treatment that involves increased capillary permeability.
• In severe refractory cases, immunoglobulins may be a useful and safe treatment to reverse this syndrome. 
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CASE DESCRIPTION
A 32-year-old woman with hereditary optic atrophy due to mutation of the OPA1 gene was admitted to hospital for dyspnoea. The patient 
was in an in vitro fertilization program. She had been treated with FSHr and GnRH for ovarian stimulation with subsequent administration of 
HCGr and implantation of two embryos free of the OPA1 mutation, 5 days before admission. Physical examination revealed grade 2 ascites 
and bilateral lower limb oedema. Blood analysis showed haemoglobin of 16.6 g/dl, sodium 133 mmol/l, albumin 3.3 g/l and βHCG 200 mU/
ml, with preserved renal and hepatic function. Transvaginal ultrasonography demonstrated enlarged ovaries with free fluid in the pelvis and 
two gestational sacs. Following the diagnosis of OHSS, fluid restriction and thromboembolic prophylaxis were started. On the sixth day after 
admission, abdominal distension and dyspnoea increased, together with hypotension and signs of haemoconcentration. Ultrasonography 
demonstrated severe pleural effusion and ascites. Electrocardiogram and echocardiogram findings were within the normal range. Serum 
albumin and intravenous furosemide were added, alongside repeated paracentesis and thoracentesis. Given the persistence of dyspnoea 
with refractory pleural effusion, a thoracic drainage tube was placed, and the patient was transferred to the intensive care unit.
In the following days symptoms persisted and a therapeutic abortion was suggested. Given the similarities between OHSS and idiopathic 
systemic capillary leak syndrome (SCLS), we offered the patient compassionate treatment with intravenous immunoglobulins (IVIG) 
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which has previously proven useful in SCLS. After administration of IVIG (0.5 g/kg/day for 3 consecutive days), the patient showed rapid 
improvement, and we were able to suspend intravenous furosemide and serum albumin and to remove the thoracic drainage tube. The 
patient was discharged, and pregnancy has continued normally to date. 
DISCUSSION
OHSS is the most severe complication associated with assisted reproductive treatments. Its pathophysiology involves increased capillary 
permeability that leads to a wide variety of signs and symptoms such as hypotension, ascites and pleural effusion. Although it is generally 
self-limiting, 5% of patients will develop life-threatening complications[1]. There is no specific treatment, and management is based on the 
control of fluid balance, thromboembolic prophylaxis, and paracentesis or thoracentesis when needed. 
As a result of this increase in capillary permeability to fluids and proteins, there is a loss of protein to fluid in the interstitial space with 
depletion of intravascular volume, associated with overproduction of vasoactive cytokines and vascular endothelial growth factor (VEGF). 
This is common to other human diseases that can also cause capillary leak syndrome such as sepsis, several drugs and SCLS[2].
We used IVIG because of the similarities with SCLS, a rare entity characterized by recurrent episodes of capillary leak syndrome with high 
mortality secondary to hypovolemic shock, acute renal failure and life-threating pulmonary oedema during the recovery phase. SCLS is 
usually associated with a monoclonal gammopathy of uncertain significance. As in OHSS, cytokines and VEGF were increased in serum 
from acutely ill subjects with SCLS[3]. Several reports and cohort studies have shown the efficacy of IVIG both in the acute phase and in the 
prevention of recurrence[4, 5]. Although the exact mechanism of action is unknown, IVIG have multiple activities including inhibitory effects 
on cytokine and VEGF production, and have been used to treat autoimmune, neurological and haematological diseases. IVIG are generally 
well tolerated and their administration during pregnancy is safe. Although new studies are needed to confirm their usefulness, the present 
case suggests that IVIG may be a useful and safe treatment for severe cases of OHSS refractory to conventional management.
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